JP2008534473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534473A5 JP2008534473A5 JP2008502386A JP2008502386A JP2008534473A5 JP 2008534473 A5 JP2008534473 A5 JP 2008534473A5 JP 2008502386 A JP2008502386 A JP 2008502386A JP 2008502386 A JP2008502386 A JP 2008502386A JP 2008534473 A5 JP2008534473 A5 JP 2008534473A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- thromboxane
- pharmaceutical composition
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229940111134 coxibs Drugs 0.000 claims 7
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims 6
- 229940111979 Thromboxane synthase inhibitor Drugs 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims 6
- 239000003768 thromboxane synthase inhibitor Substances 0.000 claims 6
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 5
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 5
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 5
- 229960001929 meloxicam Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 229960000994 lumiracoxib Drugs 0.000 claims 4
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 229960005293 etodolac Drugs 0.000 claims 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 2
- -1 luminacoxib Chemical compound 0.000 claims 2
- 229960000965 nimesulide Drugs 0.000 claims 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229960000371 rofecoxib Drugs 0.000 claims 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 2
- XUTLOCQNGLJNSA-RGVLZGJSSA-N terbogrel Chemical compound CC(C)(C)\N=C(/NC#N)NC1=CC=CC(C(=C/CCCC(O)=O)\C=2C=NC=CC=2)=C1 XUTLOCQNGLJNSA-RGVLZGJSSA-N 0.000 claims 2
- 229950006665 terbogrel Drugs 0.000 claims 2
- 230000009424 thromboembolic effect Effects 0.000 claims 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims 2
- 229960002004 valdecoxib Drugs 0.000 claims 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000014526 Conduction disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 208000024798 heartburn Diseases 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 208000015210 hypertensive heart disease Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05006325 | 2005-03-23 | ||
| PCT/EP2006/060858 WO2006100213A1 (en) | 2005-03-23 | 2006-03-20 | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534473A JP2008534473A (ja) | 2008-08-28 |
| JP2008534473A5 true JP2008534473A5 (enExample) | 2009-05-14 |
Family
ID=36694421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502386A Pending JP2008534473A (ja) | 2005-03-23 | 2006-03-20 | トロンボキサン受容体拮抗薬及びトロンボキサンシンターゼ阻害薬の組み合わせ及びｃｏｘ−２阻害薬を含む組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060217431A1 (enExample) |
| EP (1) | EP1863534A1 (enExample) |
| JP (1) | JP2008534473A (enExample) |
| CA (1) | CA2602374A1 (enExample) |
| WO (1) | WO2006100213A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035107A1 (en) | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| DE10161077A1 (de) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| EP1568369A1 (en) * | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| DE102004021281A1 (de) * | 2004-04-29 | 2005-11-24 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin |
| DE102004030409A1 (de) * | 2004-06-23 | 2006-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Neue Verwendung von Meloxicam in der Veterinärmedizin |
| NZ567627A (en) * | 2005-09-30 | 2011-08-26 | Boehringer Ingelheim Vetmed | Granulation process for making a divisible tablet containing meloxicam |
| EP2227560B1 (en) * | 2007-12-07 | 2017-10-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for the treatment and diagnosis of bone mineral density related diseases |
| WO2009089098A1 (en) | 2008-01-03 | 2009-07-16 | Musc Foundation For Research Development | Methods for the treatment of cancers |
| WO2011046853A1 (en) | 2009-10-12 | 2011-04-21 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
| MX2012010077A (es) | 2010-03-03 | 2012-09-12 | Boehringer Ingelheim Vetmed | Uso de meloxicam para el tratamiento a largo plazo de trastornos musculoesqueleticos en gatos. |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| US20150328149A1 (en) * | 2014-05-16 | 2015-11-19 | Dianne Emler | Method for Administering an Antibiotic Dosage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004521856A (ja) * | 2000-05-15 | 2004-07-22 | メルク フロスト カナダ アンド カンパニー | Ｃｏｘ−２選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物 |
| AU2001264729A1 (en) * | 2000-05-22 | 2001-12-03 | Nitromed, Inc. | Thromboxane inhibitors, compositions and methods of use related applications |
| GB0022215D0 (en) * | 2000-09-11 | 2000-10-25 | Boehringer Ingelheim Pharma | Method for the treatment of thromboembolic disorders in patients with aspirin« resistance |
| AU2002306868A1 (en) * | 2001-03-28 | 2002-10-15 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
| AU2003244913A1 (en) * | 2002-07-09 | 2004-01-23 | B.M.R.A. Corporation B.V. | Pharmaceutical combination of a thromboxane A2 receptor antagonist and a COX-2 inhibitor |
-
2006
- 2006-03-20 US US11/276,972 patent/US20060217431A1/en not_active Abandoned
- 2006-03-20 WO PCT/EP2006/060858 patent/WO2006100213A1/en not_active Ceased
- 2006-03-20 JP JP2008502386A patent/JP2008534473A/ja active Pending
- 2006-03-20 CA CA002602374A patent/CA2602374A1/en not_active Abandoned
- 2006-03-20 EP EP06725152A patent/EP1863534A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534473A5 (enExample) | ||
| JP2021504423A5 (enExample) | ||
| CA3083327A1 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| JP2020508339A5 (enExample) | ||
| CA3053991A1 (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| JP2009102342A5 (enExample) | ||
| JP2005519923A (ja) | シクロオキシゲナーゼ−２選択的阻害剤ならびに風邪および咳止め薬の組み合わせを用いる風邪および咳の治療ならびにそれらの組成物 | |
| JP2010526101A5 (enExample) | ||
| TW201249432A (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| HUP9902889A2 (hu) | 3-Fenil-4-(4-metilszulfonil)-fenil-2-(5H)-furanon alkalmazása gyulladáscsökkentő gyógyszerkészítmény előállítására, és az ilyen készítmények | |
| JP2019218379A5 (enExample) | ||
| JP2020515523A5 (enExample) | ||
| US20060217431A1 (en) | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor | |
| JP2005533830A5 (enExample) | ||
| US20170319519A1 (en) | Combination for the treatment of conditions involving muscular pain | |
| JP2005524618A (ja) | シクロオキシゲナーゼ−２選択的阻害剤およびアスピリンの組み合わせを用いる、疼痛、炎症および炎症性疾患の治療 | |
| WO2005074930A1 (en) | Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids | |
| JPH10507445A (ja) | 神経変性障害の治療におけるシクロオキシゲナーゼ阻害剤の使用 | |
| JP2016505628A5 (enExample) | ||
| EP2332930A1 (en) | Salts of duloxetine and NSAIDs for the treatment of pain | |
| CN104000814B (zh) | 一种防治痛风性关节炎的药物组合物及其用途 | |
| WO2018004498A1 (en) | Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation | |
| US20080306146A1 (en) | Dosing Regimens for Cox-2 Inhibitor | |
| Gislason | NSAIDs and cardiovascular risk | |
| Sarkar et al. | The Toxicological Consequences of Naproxen |